Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Hohenstein

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Deutsche Medizinische Wochenschrift (1946)|October 2, 2012
[Diabetes and the kidneys]B Hohenstein, C Hugo
Der Internist|March 13, 2019
[Membranoproliferative glomerulonephritis and C3 glomerulopathy]B Hohenstein, K Amann, J Menne
Atherosclerosis. Supplements|May 5, 2015
Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long runE Groß, B Hohenstein, U Julius
Atherosclerosis. Supplements|May 5, 2015
Actual situation of lipoprotein apheresis in Saxony in 2013U Emmrich, B Hohenstein, U Julius
Atherosclerosis. Supplements|January 30, 2013
Immunoadsorption for connective tissue diseaseB Hohenstein, S R Bornstein, M Aringer
Atherosclerosis. Supplements|May 5, 2015
Adverse events of lipoprotein apheresis and immunoadsorption at the Apheresis Center at the University Hospital DresdenJ Dittrich-Riediger, U Schatz, B Hohenstein, et al.
Shock (Augusta, Ga.)|January 5, 2002
Modulating IL-6 and IL-10 levels by pharmacologic strategies and the impact of different extracorporeal circulation parameters during cardiac surgeryF Harig, B Hohenstein, J von der Emde, et al.
Atherosclerosis. Supplements|May 5, 2015
Effects of different lipoprotein apheresis methods on serum protein levelsU Julius, G Siegert, H Kostka, et al.
Atherosclerosis. Supplements|November 4, 2017
Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemiaS Tselmin, G Müller, U Schatz, et al.
Atherosclerosis. Supplements|November 4, 2017
Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational studyU Schatz, S Tselmin, G Müller, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Deutsche Medizinische Wochenschrift (1946)|October 2, 2012
[Diabetes and the kidneys]B Hohenstein, C Hugo
Der Internist|March 13, 2019
[Membranoproliferative glomerulonephritis and C3 glomerulopathy]B Hohenstein, K Amann, J Menne
Atherosclerosis. Supplements|May 5, 2015
Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long runE Groß, B Hohenstein, U Julius
Atherosclerosis. Supplements|May 5, 2015
Actual situation of lipoprotein apheresis in Saxony in 2013U Emmrich, B Hohenstein, U Julius
Atherosclerosis. Supplements|January 30, 2013
Immunoadsorption for connective tissue diseaseB Hohenstein, S R Bornstein, M Aringer
Atherosclerosis. Supplements|May 5, 2015
Adverse events of lipoprotein apheresis and immunoadsorption at the Apheresis Center at the University Hospital DresdenJ Dittrich-Riediger, U Schatz, B Hohenstein, et al.
Shock (Augusta, Ga.)|January 5, 2002
Modulating IL-6 and IL-10 levels by pharmacologic strategies and the impact of different extracorporeal circulation parameters during cardiac surgeryF Harig, B Hohenstein, J von der Emde, et al.
Atherosclerosis. Supplements|May 5, 2015
Effects of different lipoprotein apheresis methods on serum protein levelsU Julius, G Siegert, H Kostka, et al.
Atherosclerosis. Supplements|November 4, 2017
Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemiaS Tselmin, G Müller, U Schatz, et al.
Atherosclerosis. Supplements|November 4, 2017
Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational studyU Schatz, S Tselmin, G Müller, et al.
Pageof 2